Media

Event
Medical
Corporate
Corporate
2020-10-21

Business Opportunities in Genomics – Immunotherapy & biomarkers

Microsatellite instability (MSI) and Tumor Mutational Burden (TMB) are two important biomarkers to predict the response of immunotherapy. ACT Genomics is dedicated to optimize the accuracy of TMB testing in Friends of Cancer Research (FoCR) Global Project

Published:

Hong Kong

Author(s):

Dr. Hua-Chien Chen

Corporate
2020-10-05

Business Opportunities in Genomics — ACT Genomics co-organizes Hong Kong International Oncology Symposium

ACT Genomics is honored to be the coorganizer of The 7th HKIOS, to dedicate in the cancer precision medicine and to build a more health society.

Published:

Hong Kong

Author(s):

Dr. Hua-Chien Chen

Corporate
2020-10-01

Business Opportunities in Genomics — Provide discounts on cancer genomic profiling for insurance plan

To broaden the application of cancer genomic profiling and enable more cancer patients to use advanced medical technology, ACT Genomics continues the cooperation with AIA Hong Kong and provide discounts on cancer genomic profiling for one year program.

Published:

Hong Kong

Author(s):

Dr. Hua-Chien Chen

Corporate
2020-09-30

Upgrade of Cancer Prevention Insurance

Physicians can start appropriate treatment strategy according to cancer genomic mutation and ACT Genomics will provide 10 % discounts on all ACT Genomics cancer genomic profiling items to 2021.09.25

Published:

Taipei

Author(s):

Economy Daily News

Medical
2020-09-16

Genomic sequencing helps the combination of two immune checkpoint inhibitors to control stage IV nasopharyngeal carcinoma

A cancer patient is identified by comprehensive genomic profiling as TMB-H with better response to immunotherapy and the combination of two immune checkpoint inhibitors is used to control stage IV nasopharyngeal carcinoma successfully

Published:

Taipei

Author(s):

HealthNews

Corporate
2020-09-08

Business Opportunities in Genomics — A big difference in Eastern & Western melanoma patients

Immunotherapy shows better efficacy in Western melanoma patients than Asian patients. ACT Genomics cooperates with medical institutes to understand the molecular information of melanoma for better treatment.

Published:

Hong Kong

Author(s):

Dr. Hua -Chien Chen

Corporate
2020-08-24

Business Opportunities in Genomics-NGS can help evaluating immunotherapy

Via Next Generation Sequencing, TMB-H cancer patients have positive progress after using immunotherapy

Published:

Hong Kong

Author(s):

Dr. Hua-Chien Chen

Corporate
2020-08-20

Business Opportunities in Genomics-Using genomic profiling to find suitable targeted drugs

Through ideal medical perspective, genomic profiling can also enable patients to maintain normal life and quality beside providing suitable medical solutions.

Published:

Hong Kong

Author(s):

Dr. Hua-Chien Chen

Corporate
2020-08-20

Business Opportunities in Genomics-New targeted drugs for lung cancers

NGS can help cancer patients treat cancer with the right drugs, and through more targeted drugs, it will be easier to treat lung cancer.

Published:

Hong Kong

Author(s):

Dr. Hua-Chien Chen

Medical
2020-08-03

The special disease progress of a 62-year-old lung cancer patient is controlled after performing genomic profiling sequencing twice

The treatment options for late-stage lung cancer treatment are limited and NGS can overcome brain metastases mostly seen in late-stage.

Published:

Taipei

Author(s):

Healthnews